MDM2 is well-established in MM; Jovanović et al. (2018) showed that it suppresses p53 by promoting its degradation, forming a negative feedback loop, and that MDM2 inhibition may reactivate p53 and provide therapeutic benefit [51]. Here, TP53 is linked to Miyoshi myopathy.